Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...
AZ said in the summer that anifrolumab had met its objectives in the phase 3 TULIP-2 trial, around a year after it flunked an earlier study (TULIP-1) which had caused many to dismiss any prospect ...
UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus ... GSK's Benlysta (belimumab), AstraZeneca's Saphnelo (anifrolumab), and Otsuka's Lupkynis (voclosporin).
Hosted on MSN1mon
Anifrolumab Tied to Less Organ Damage for Patients With LupusTHURSDAY, Feb. 20, 2025 (HealthDay News) -- For patients with moderately to severely active systemic lupus erythematosus (SLE), anifrolumab is associated with less organ damage after 208 weeks ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback